Abstract
Advances in the molecular biology of oncogenesis have established a key role for transcription factors in malignant transformation. In some cases the activity of the transcription factor itself is altered by mutation. In many other cases, the activity of the transcription factor is affected by mutations in upstream signaling or regulatory proteins. This review highlights four transcription factors - Stat3, Stat5, NF-kB, and HIF-1 - which are associated with cancer development. The evidence for the involvement of these factors in oncogenesis is reviewed. Further, we examine the efforts to specifically target these transcription factors for therapeutic intervention. Such strategies include using peptidomimetics, antisense oligonucleotides, small molecule inhibitors, and G-quartet oligonucleotides. Inhibition of transcription factor activity may occur at the level of activation, translocation, or DNA binding. Application of these approaches to in vitro and in vivo models of tumorigenesis is discussed.
Keywords: ap family, apoptosis, oncogenesis, stats, src-homology (sh), janus kinases (jaks), reporter gene assays, oligodeoxynucleotides
Current Pharmaceutical Design
Title: Targeting Transcription Factors for Cancer Therapy
Volume: 11 Issue: 22
Author(s): M. S. Redell and D. J. Tweardy
Affiliation:
Keywords: ap family, apoptosis, oncogenesis, stats, src-homology (sh), janus kinases (jaks), reporter gene assays, oligodeoxynucleotides
Abstract: Advances in the molecular biology of oncogenesis have established a key role for transcription factors in malignant transformation. In some cases the activity of the transcription factor itself is altered by mutation. In many other cases, the activity of the transcription factor is affected by mutations in upstream signaling or regulatory proteins. This review highlights four transcription factors - Stat3, Stat5, NF-kB, and HIF-1 - which are associated with cancer development. The evidence for the involvement of these factors in oncogenesis is reviewed. Further, we examine the efforts to specifically target these transcription factors for therapeutic intervention. Such strategies include using peptidomimetics, antisense oligonucleotides, small molecule inhibitors, and G-quartet oligonucleotides. Inhibition of transcription factor activity may occur at the level of activation, translocation, or DNA binding. Application of these approaches to in vitro and in vivo models of tumorigenesis is discussed.
Export Options
About this article
Cite this article as:
Redell S. M. and Tweardy J. D., Targeting Transcription Factors for Cancer Therapy, Current Pharmaceutical Design 2005; 11 (22) . https://dx.doi.org/10.2174/1381612054546699
DOI https://dx.doi.org/10.2174/1381612054546699 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Costimulation, Coinhibition and Cancer
Current Cancer Drug Targets Disorders of Protein Biogenesis and Stability
Protein & Peptide Letters Topical Application of <i>In Vitro</i> Transcribed mRNA to the Airways as a Novel Gene Therapy Approach for the Treatment of Cystic Fibrosis
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Non-Invasive Imaging of Complicated Osteomyelitis: The Added Value of Scintigraphic Techniques
Current Radiopharmaceuticals Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Genetically Modified Hepatitis B Surface Antigen: A Powerful Vaccine Technology for the Delivery of Disease-Associated Foreign Antigens
Current Drug Therapy Anti-cancer Nitrogen-Containing Heterocyclic Compounds
Current Organic Chemistry CC and CXC Chemokines in Breastmilk are Associated with Mother-to- Child HIV-1 Transmission
Current HIV Research Aryltetralin-type Lignan of Podophyllum: A Comprehensive Review
The Natural Products Journal Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets Preclinical Evaluation of In-111 and Ga-68 Labelled Minigastrin Analogues for CCK-2 Receptor Imaging
Current Radiopharmaceuticals DNA Repair Inhibitors: The Next Major Step to Improve Cancer Therapy
Current Topics in Medicinal Chemistry A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance
Current Pharmaceutical Design Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets Some Recent Synthetic Development on Compounds with Potent Activities on Hormone-sensitive Breast Cancers
Current Organic Chemistry Biomacromolecule-Functionalized Nanoparticle-Based Conjugates for Potentiation of Anticancer Therapy
Current Cancer Drug Targets QSRR and QSAR Studies of Antitumor Drugs in View of their Biological Activity Prediction
Medicinal Chemistry